The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions

Breast

Volumn 17, Issue 5, 2008, Pages 436-440

  Mok, Kelly ^a   Juraskova, Ilona ^b   Friedlander, Michael ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aromatase inhibitors; Breast cancer; Intervention; Review; Sexual functioning

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ASTROGLIDE; ESTROGEN; EXEMESTANE; LETROZOLE; LUBRICATING AGENT; OLIVE OIL; PLACEBO; POLYCARBOPHIL; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; AUSTRALIA; BELGIUM; BREAST CANCER; CANADA; CANCER RECURRENCE; CANCER SURVIVAL; CINAHL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPAREUNIA; ELECTROMYOGRAPHY; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; LIBIDO DISORDER; MANOMETRY; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MENOPAUSAL SYNDROME; PHYSIOTHERAPY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SOCIAL PSYCHOLOGY; UNITED KINGDOM; UNITED STATES; VAGINAL DRYNESS;

EID: 53149087457     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.04.001     Document Type: Article

References (33)

1. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR); 2001.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
3. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937
4. Howell A., Cuzick J., Baum M., Buzdar M., Dowsett M., Forbes J.F., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
5. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
6. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
7. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369 (2007) 559-570
8. Boccardo F. Switching to anastrozole (ANA) vs. continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. In: Paper presented at: 41st annual meeting of the American Society of Clinical Oncology (ASCO). Orlando, United States; 2005.
9. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 366 (2005) 455-462
10. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomised trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
11. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 97 (2005) 1262-1271
12. National Breast Cancer Centre. Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. Available from: (July 2006). www.nbcc.org.au
13. Richardson H., Johnston D., Pater J., Goss P., and on behalf of the MAP.3 Consortium. The National Cancer Institute of Canada Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 14 3 (2007) 89-96
14. Day R., Ganz P., Costantino J., Cronin W.M., Wickerham D.L., and Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the national surgical adjuvant breast and bowel project P-1 study. J Clin Oncol 17 (1999) 2659-2669
15. Mortimer J., Boucher L., Baty J., Knapp D.L., Ryan E., and Rowland J.H. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 17 (1999) 1488-1492
16. Mourits M.J., Bockermann I., de Vries E.G., van der Zee A.G., ten Hoor K.A., van der Graaf W.T., et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 86 (2002) 1546-1550
17. ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: long term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
18. Fallowfield L., Cella D., Cuzick S., Locker G., and Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22 (2004) 4261-4271
19. Fallowfield L., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., et al. Quality of life in the intergroup exemestane study: a randomised trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24 (2006) 910-917
20. Whelan T., Goss P., Ingle J., Pater J.L., Tu D., Pritchard K., et al. Assessment of quality of life in MA 17: a randomised, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 28 (2005) 6931-6940
21. Asmar L., Cantrell J., Vukelja J., Pippen J.E., O'Shaughnessy J., Blum J.L., et al. A planned comparison of menopausal symptoms during the first year in 1000 patients receiving either exemestane of tamoxifen in a double blind adjuvant hormonal study. J Clin Oncol 22 (2004) 6s [suppl; abstr 516]
22. Morales L., Neven P., Timmerman D., Christiaens M., Vergote I., Van Limbergen E., et al. Acute effects of tamoxifen and third generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15 (2004) 753-760
23. Basson R. Women's sexual dysfunction: revised and expanded definitions. CMAJ 172 10 (2005) 1327-1333
24. Jones L.R.A. The use of validated questionnaires to assess female sexual dysfunction. World J Urol 20 (2002) 89-92
25. Thirlaway K., Fallowfield L., and Cuzick J. The sexual activity questionnaire: a measure of women's sexual functioning. Qual Life Res 5 (1996) 81-90
26. Hickey M., Davis S.R., and Sturdee D.W. Treatment of menopausal symptoms: what shall we do now?. Lancet 366 9483 (2005) 409-421
27. Holmberg L., and Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 363 (2004) 453-455
28. Von Schoultz E., and Rutqvist L.E. Menopausal hormone therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97 (2005) 533-535
29. Vassilopoulou-Sellin R., Asmar L., Hortobagyi G.N., Klein M.J., McNeese M., Singletary S.E., et al. Estrogen replacement therapy after localised breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17 (1999) 1482-1487
30. Kendall A., Dowsett M., Folkerd E., and Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17 (2006) 584-587
31. Nedrow A., Miller J., Walker M., Nygren P., Hoyt Huffman L., and Nelson H.D. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 166 (2006) 1453-1465
32. Ganz P., Greendale G., Petersen L., Zibecchi L., Kahn B., and Belin T.R. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 92 (2000) 1054-1064
33. Mok K., Mireskandari S., Juraskova I., Jarvis S., Peate M., Friedlander M., et al. OVER (olive oil, vaginal exercises and replens) come: an intervention study to improve sexual function in women with breast cancer. Psychooncology 15 S2 (2006) S778